Keeping you updated
Pioneering biotech company strengthened by senior appointments to bolster capabilities in research, product development and clinical trials of COVID-19 drug. Company ready to accelerate the development of Alfacyte™ – ILC’s lead hybrid interferon designed to combat viral infections including COVID-19.
COVID: Antiviral drugs that boost humans’ ‘interferon’ immune response can help tackle current and future pandemics – Professor William Stimson
As we live through the most rapidly evolving viral environment the world has seen, there is a critical need for effective and safe antiviral medicines to meet the challenges of today and the inevitable threats of tomorrow. Worldwide, we are
ILC Therapeutics, a UK-based biotechnology company and pioneer in the discovery and development of a ground-breaking new class of interferon drugs…
ILC Therapeutics, a UK-based biotechnology company and pioneer in the discovery and development of a new class of interferon drugs…
An interview with Founder & Chief Scientific Officer William Stimson in Drug Discovery World.
ILC Therapeutics has welcomed NHS plans to make Covid-19 treatments available to patients as soon as possible.
ILC Therapeutics has secured substantial funding from its first international investor, Medical Incubator Japan (MIJ).
ILC Therapeutics has confirmed that its unique synthetic Interferon called Alfacyte™ is 15 to 20 times more effective at preventing the spread of SARS-CoV-2 Independent research at the University of St Andrews demonstrated the superior effectiveness of Alfacyte™ in vitro
ILC Therapeutics has struck a research partnership with the University of St Andrews in a bid to progress a therapeutic drug which can treat COVID-19 towards clinical trials.